Published online February 29, 2008
PEDIATRICS Vol. 121 No. 3 March 2008, pp. e506-e512 (doi:10.1542/peds.2007-1129)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Glanz, J.
Right arrow Articles by Hambidge, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glanz, J.
Right arrow Articles by Hambidge, S.
Related Collections
Right arrow Blood

ARTICLE

A Population-Based, Multisite Cohort Study of the Predictors of Chronic Idiopathic Thrombocytopenic Purpura in Children

Jason Glanz, PhDa, Eric France, MD, MSPHa,b, Stan Xu, PhDa, Taru Hayes, MDc and Simon Hambidge, PhDa,c,d

a Institute for Health Research
b Department of Preventive Medicine, Kaiser Permanente Colorado, Denver, Colorado
c Department of Pediatrics, University of Colorado School of Medicine, Denver, Colorado
d Community Health Services, Denver Health, Denver, Colorado

OBJECTIVE. The objective of this study was to identify risk factors for developing chronic idiopathic thrombocytopenic purpura in a cohort of pediatric patients with idiopathic thrombocytopenic purpura.

METHODS. We conducted a retrospective cohort analysis of 259 children who were diagnosed with idiopathic thrombocytopenic purpura between 1991 and 2000 at 1 of 8 managed care organizations that comprise the Vaccine Safety Datalink. We reviewed the charts of 595 potential patients with idiopathic thrombocytopenic purpura from the 8 Vaccine Safety Datalink sites and excluded patients with known causes of thrombocytopenia. Chronic idiopathic thrombocytopenic purpura was defined as having thrombocytopenia for 6 months beyond the initial diagnosis. The risk for developing chronic idiopathic thrombocytopenic purpura was assessed using simple and multivariable analyses.

RESULTS. Of the 259 cases of idiopathic thrombocytopenic purpura, 197 (76%) were acute, 60 (23%) were chronic, and 2 (1%) could not be determined. Among the acute cases, the mean duration of illness was 22 days. There was 1 serious bleeding outcome in the cohort. In multivariable regression analysis, the patients with chronic illness were older, less likely to present with mucosal bleeding, less likely to have had an acute illness before diagnosis, and more likely to present with a platelet count >20000/µL than children with acute idiopathic thrombocytopenic purpura. In particular, children whose illness was diagnosed at ≥10 years of age and who had platelet counts ≥20000/µL had an approximate fivefold risk for progressing to chronic disease when compared with children who presented at ≤2 years of age with platelet counts <20000/µL.

CONCLUSIONS. Although idiopathic thrombocytopenic purpura tends to be a benign and self-limited condition, acute and chronic idiopathic thrombocytopenic purpura seem to be distinct illnesses defined by age, platelet count, bleeding symptoms, and the presence of acute illness before diagnosis. Physicians should be aware of these differences when advising their patients and families.

Key Words: ITP • thrombocytopenia • children • epidemiology

Abbreviations: ITP—idiopathic thrombocytopenic purpura • MMR—measles-mumps-rubella • MCO—managed care organization • VSD—Vaccine Safety Datalink • ICD-9—International Classification of Diseases, Ninth Revision • CI—confidence interval • RR—relative risk

Accepted Jul 20, 2007.